Experimental CBL-514 Shot Shows Visceral Fat Reduction
Early MRI data show lower deep abdominal fat, but larger trials are needed
Key Developments:
- CBL-514 lowered visceral fat in a Phase 2 analysis
- MRI results showed effects lasting beyond treatment
- Phase 3 trials are now evaluating safety and effectiveness
(SciTech Daily) — October 08, 2026: An experimental injectable treatment has shown a reduction in visceral fat in an early human study, adding to evidence that CBL-514 may be able to target both the fat stored beneath the skin and deeper abdominal deposits surrounding internal organs.
Researchers from the University of Alabama at Birmingham and Caliway Biopharmaceuticals analysed MRI data from participants in two Phase 2 studies to examine whether the treatment affected visceral adipose tissue, or VAT. The analysis involved a relatively small subgroup, making the findings preliminary rather than evidence of an established treatment.
Used car imports in Pakistan surge 4,600% amid soaring demand for foreign vehicles
IMF Reaches Staff-Level Agreement With Pakistan on Fourth EFF Review
Pakistan Wins 11 Tech Awards at Major Asian Tech Event
CBL-514 is designed to work differently from commonly used appetite-regulating medicines. Rather than primarily reducing food intake, the investigational compound is intended to trigger apoptosis, or programmed cell death, in fat cells. Earlier Phase 2 research had already reported reductions in abdominal subcutaneous fat.
In the MRI analysis, participants received injections into the lower abdomen at intervals of about three weeks, with doses reaching up to 600 milligrams. The number of injections was adjusted according to the thickness of abdominal fat.
A 2026 study presented at the European Association for the Study of Diabetes (EASD) annual meeting found that an experimental injection called CBL-514 reduced visceral abdominal fat in humans. CREDIT: Healthy Harbor.
Four weeks after the final treatment, average visceral-fat volume in the CBL-514 group was 12.01% below its starting level, while the placebo group recorded a 5.68% increase. At a later follow-up, the treatment group remained 10.45% below its baseline visceral-fat volume, compared with an 11.76% increase among participants receiving placebo. The reported difference between the groups at that stage was 22.21 percentage points.
FIR against Rahul Gandhi, Priyanka Gandhi for ‘assaulting cops’ during Delhi protest
Nana Patekar Has Long Held a Strongly Critical View of Pakistan
Veteran Bollywood Actor Nana Patekar Passes Away at 75 After Cardiac Arrest in Goa
The findings were based on MRI measurements rather than estimates of future health outcomes. Researchers have suggested that reducing visceral fat could potentially have metabolic benefits, but the current data do not establish that CBL-514 reduces the risk of diabetes, heart disease or stroke.
Dr. W. Timothy Garvey of the University of Alabama at Birmingham said: “We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss.”
Garvey added that the more important question would be whether reductions in body weight and visceral fat translate into improvements in measures such as blood pressure and cholesterol. Those broader benefits still require confirmation in further clinical research.
AAP leader in Punjab alleges bride posed as PCS officer, fled with gold and valuables; six booked
Pakistani Troops Already Deployed in Saudi Arabia to Protect Two Holy Mosques: ISPR
Lightning Strike Damages IndiGo Airbus A320 on Patna-Lucknow Flight, All 110 Safe
The earlier Phase 2 programme also found a reduction in subcutaneous fat. At an eight-week follow-up, 69.6% of participants receiving CBL-514 had achieved at least 150 millilitres of subcutaneous-fat reduction, compared with none in the placebo group.
The treatment was generally tolerated in the reported studies. Pain, swelling and redness at injection sites were among the reported reactions, with most described as mild to moderate and temporary. No serious adverse events were reported in the MRI analysis.
US researchers say the experimental drug, known as CBL-514 , could in the future offer a less invasive alternative to aesthetic procedures such as liposuction, particularly for areas where fat is more difficult to remove. CREDIT: Express.
Garvey described the approach as “a highly innovative approach to obesity pharmacotherapy that has produced some remarkable results in early human trials.” However, the experimental status of CBL-514 remains important, as the available evidence is still based on relatively early-stage clinical research.
Governor’s Rule Is the Last Option, We Are Trying to Avoid It: Khawaja Asif
Every FIR a medal, target is 100: Rahul Gandhi
Researchers are also examining whether removing some fat cells could affect weight regain after treatment with GLP-1-based medicines. In animal experiments, combining CBL-514 with tirzepatide produced greater weight loss and appeared to reduce subsequent weight regain compared with tirzepatide alone. These findings have not yet been demonstrated in humans and should therefore be considered preclinical evidence.
The programme has now advanced into Phase 3 testing. Caliway says its global pivotal SUPREME-01 study has begun enrolling participants to evaluate CBL-514 for abdominal subcutaneous-fat reduction, while additional Phase 3 development is underway.
Caliway advances CBL-514 with FDA-cleared Phase 2 tirzepatide study, Phase 3 SUPREME-01 enrollment and new visceral fat data headed to EASD. CREDIT: Pharmacally.
The latest evidence therefore points to a potentially different approach to targeted fat reduction, but it is too early to determine whether CBL-514 will provide lasting weight-management or metabolic benefits. Larger, controlled Phase 3 trials will be needed to establish its effectiveness, safety and longer-term outcomes.
UN Secretary-General Antonio Guterres Meets Field Marshal Asim Munir at GHQ
Former Data Darbar Khateeb Found Guilty of Financial Irregularities and Misconduct
Pakistan Navy Ship Yarmook Seizes Drugs Worth $96 Million in Arabian Sea Operations
Fateh-IV: Pakistan’s Extended Reach and the Changing India-Pakistan Strategic Equation
Begum Akhtar, the ‘Queen of Ghazals,’ Remembered on Her 112th Birth Anniversary Today
Delta A350 and Air Canada 777 Collide at Los Angeles International Airport, No Injuries Reported
Former German Intelligence Chief Arrested on Espionage Charges
Stay tuned to Baaghi TV for more. Download our app for the latest news, updates & uncensored content!
Further Reads
